Naproxen: a review of its pharmacological properties and therapeutic efficacy and use.
Naproxen2, (+)-6-methoxy-alpha-methyl-2-naphthalene acetic acid, is a new non-steroidal anti=inflammatory agent advocated for use in rheumatiod arthritis, degenerative joint disease and ankylosing spondylitis. Published data suggest that in rheumatiod arthritis, naproxen 500mg daily comparable in efficacy with moderate doses of aspirin (3.6 to 4g daily) or 150mg daily of indomethacin, but generally causes fewer and milder side-effects than these drugs at the dosages used and can be given less frequently (12-hourly). Encouraging intial results have been reproted from its use in other inflammatory joint disorders, including acute gout and juvenile rheumatiod arthritis. It has compared favourably with indomethacin in ostioarthrosis of the hip of knee. Its exact place in the management of ankylosing spondylitis remains to be determined.
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D003094:Collagen / Q000378:metabolism; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D006073:Gout / Q000188:drug therapy; D006801:Humans; D007408:Intestinal Absorption; D007592:Joint Diseases / Q000188:drug therapy; D007700:Kinetics; D008297:Male; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D009280:Naphthaleneacetic Acids; D009288:Naproxen / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D011485:Protein Binding; D051381:Rats; D013167:Spondylitis, Ankylosing / Q000188:drug therapy
D009280:Naphthaleneacetic Acids; D009288:Naproxen; D003094:Collagen; D001241:Aspirin